Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.

Journal: Journal for immunotherapy of cancer
Published Date:

Abstract

BACKGROUND: Currently, only a fraction of patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) experience a durable clinical benefit (DCB). According to NCCN guidelines, Programmed death-ligand 1 (PD-L1) expression status determined by immunohistochemistry (IHC) of biopsies is the only clinically approved companion biomarker to trigger the use of ICI therapy. Based on prior work showing a relationship between quantitative imaging and gene expression, we hypothesize that quantitative imaging (radiomics) can provide an alternative surrogate for PD-L1 expression status in clinical decision support.

Authors

  • Wei Mu
    Key Laboratory of Pesticide Toxicology&Application Technique, College of Plant Protection, Shandong Agricultural University, Tai'an 271018, China.
  • Lei Jiang
    Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China.
  • Yu Shi
    NIH BD2K Program Centers of Excellence for Big Data Computing-KnowEng Center, Department of Computer Science, University of Illinois at Urbana-Champaign , Champaign, Illinois.
  • Ilke Tunali
    Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Jhanelle E Gray
    Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Evangelia Katsoulakis
    Department of Radiation Oncology, University of South Florida, Tampa, Florida, USA.
  • Jie Tian
    CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.
  • Robert J Gillies
    Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.
  • Matthew B Schabath
    Associate Member, Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.